Evidence map›Paper›PMID 35895384›Full record

ArticleBiomedical chromatography : BMC2022

Quantitation of navtemadlin in human plasma and brain tissue by liquid chromatography-tandem mass spectrometry.

Amanda B Kagan, Nicole M Anders, Avelina Hemingway, Eudocia Q Lee, Kevin R Kelly, Hans C Lee, Meng Xu-Welliver, Richard Piekarz, Michelle A Rudek

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedical chromatography : BMC, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Amanda B KaganDivision of Clinical Pharmacology, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.ORCID https://orcid.org/0000-0002-1953-2029
Nicole M AndersThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA.
Avelina HemingwayThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA.
Eudocia Q LeeDana-Farber Cancer Institute, Boston, MA, USA.
Kevin R KellyDivision of Hematology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA.
Hans C LeeDepartment of Lymphoma/Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID https://orcid.org/0000-0001-8545-3292
Meng Xu-WelliverDepartment of Radiation Oncology, The Ohio State University, Columbus, OH, USA.
Richard PiekarzInvestigational Drug Branch, Cancer Therapy Evaluation Program (CTEP), National Cancer Institute, Bethesda, MD, USA.ORCID https://orcid.org/0000-0002-3591-7893
Michelle A RudekDivision of Clinical Pharmacology, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.ORCID https://orcid.org/0000-0001-5739-6868
Johns Hopkins University · USDana-Farber Cancer Institute · USNational Cancer Institute · USThe Ohio State University · USThe University of Texas MD Anderson Cancer Center · USUniversity of Southern California · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
QAQC Johns Hopkins Institute for Clinical and Translational ResearchUL1TR003098 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2019 to 2023
$57.7M
The Johns Hopkins Translational Science Team for the ET-CTNUM1CA186691 · NCI · JOHNS HOPKINS UNIVERSITY · PI Jan Hendrik Beumer, Michael A Carducci · 2014 to 2026
$21.9M
Clinical Pharmacology Training ProgramT32GM066691 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI Matthew Michael Ippolito · 2003 to 2026
$6.4M
The Chesapeake-Ohio Pharmacokinetics Core for The ETCTNU24CA247648 · NCI · JOHNS HOPKINS UNIVERSITY · PI Jan Hendrik Beumer, Mitch A Phelps · 2020 to 2026
$3.6M
UPLC with Tandem MS for Sensitive Quantitative Analysis of Small MoleculesS10RR026824 · NCRR · JOHNS HOPKINS UNIVERSITY · PI RUDEK, MICHELLE A · 2010 to 2010
$429k
NCATS NIH HHS UL1 TR003098NCATS NIH HHS UL1TR003098NCI NIH HHS P30 CA006973NCI NIH HHS U24 CA247648NCI NIH HHS U24CA247648NCI NIH HHS UM1 CA186691NCI NIH HHS UM1CA186691NCRR NIH HHS S10 RR026824NIGMS NIH HHS T32 GM066691NIH HHS P30CA006973NIH HHS S10RR026824NIH HHS T32GM066691
6 · The paper itself

Abstract

Navtemadlin is an orally bioavailable small molecule that blocks the protein-protein interaction between murine double minute 2 protein (MDM2) and the tumor suppressor protein p53, leading to p53-mediated cell cycle arrest and apoptosis. It is being evaluated in clinical trials for a variety of malignancies, both as a single agent and in combination regimens. A sensitive, robust LC-tandem mass spectrometry (LC-MS/MS) method was developed to quantitate navtemadlin in plasma, and this method was also validated using brain tissue homogenate. Sample preparation involved protein precipitation of plasma or brain tissue homogenate using acetonitrile. Navtemadlin, navtemadlin glucuronide, and the internal standard, D

Indexed as

Tandem Mass SpectrometryTumor Suppressor Protein p53AcetonitrilesAnimalsBrainChromatography, High Pressure LiquidChromatography, LiquidGlucuronidesHumansMiceProto-Oncogene Proteins c-mdm2Reproducibility of ResultsAcetonitrilesGlucuronidesProto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53assaynavtemadlintandem mass spectrometryvalidation

Identifiers

PMID35895384
PMCPMC9662208
OpenAlexW4288067187

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.